



- (51) International Patent Classification:
A61K 38/51 (2006.01)
- (21) International Application Number:
PCT/EP2015/052962
- (22) International Filing Date:
12 February 2015 (12.02.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
1451100 12 February 2014 (12.02.2014) FR
- (71) Applicant: **ERYTECH PHARMA** [FR/FR]; 60 avenue
Rockefeller, F-69008 Lyon (FR).
- (72) Inventors: **GODFRIN, Yann**; c/o ERYTECH PHARMA
60 avenue Rockefeller, F-69008 Lyon (FR). **BOURGEAUX, Vanessa**; c/o ERYTECH PHARMA 60
avenue Rockefeller, F-69008 Lyon (FR). **GAY, Fabien**;
c/o ERYTECH PHARMA 60 avenue Rockefeller, F-69008
Lyon (FR). **CORTESE, Thomas**; c/o GTP Technology
Bâtiment Gould 52 l'Occitane, F-31670 Labège (FR).
- (74) Agents: **COLOMBET, Alain** et al.; Lavoix, 62, rue de
Bonnell, F-69003 Lyon (FR).

- (81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING ERYTHROCYTES ENCAPSULATING A PLP-DEPENDENT
ENZYME AND ITS COFACTOR

(57) Abstract: The invention relates to a pharmaceutical composition containing a PLP-dependent enzyme and optionally its
cofactor, pyridoxal phosphate (PLP), and/or a phosphate or non-phosphate precursor of PLP, its use as a drug, its production method
and a therapeutic treatment method related to it. The pharmaceutical composition comprises erythrocytes and a pharmaceutically ac-
ceptable vehicle, the erythrocytes encapsulating the PLP-dependent enzyme. The PLP-dependent enzyme may be methioninase, tyr-
osine phenol-lyase, tyrosine aminotransferase or cystathionine beta-synthase.

